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Overweight is a proposed risk factor for psoriasis. How­
ever, evidence from prospective studies is limited. The 
aim of this study was to investigate the association be­
tween overweight, weight gain and risk of psoriasis, and 
potential synergism with smoking, within a population­
based cohort including 8,752 individuals followed from 
1994 up to 2008. There was a 32% increased odds of 
psoriasis from a body mass index (BMI) of 27 kg/m2, 
in multi variable logistic regression analysis, further in­
creasing to 43% at BMI 28 kg/m2, and to 71% at BMI 
≥ 30 kg/m2 in non­smokers. There was a dose­response 
association between weight gain from age 25 years, with 
up to 90% higher odds of psoriasis from middle age, in­
dependent of weight category. There was no indication 
of a synergism between overweight and smoking, and no 
sex interaction. Overweight and weight gain represent 
modifiable risk factors that may be targets for primary 
prevention of psoriasis. Key words: cohort; longitudinal; 
obesity; overweight; psoriasis; smoking.
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Psoriasis is a chronic inflammatory skin disease that is 
associated with substantial morbidity as well as several 
comorbid conditions, including diabetes and cardiovas-
cular disease (1–5). Studies from different populations, 
including a recent report from Norway (6–9), suggest that 
the prevalence of psoriasis may have doubled over recent 
decades, now reaching a lifetime prevalence of 5.8–11% 
in Scandinavia (6, 8, 10). Psoriasis is a multifactorial 
disease developing in genetically susceptible individuals. 
However, the understanding of how lifestyle influences 
psoriasis risk remains limited (11). Overweight and 
obesity constitute a major lifestyle epidemic. Numerous 
cross-sectional and case-control studies have reported 
positive associations between overweight, obesity and 
psoriasis (12–14). However, only 3 longitudinal studies 
have investigated whether overweight predates psoriasis 
in adults. In a nested case-control study from the UK, 
overweight individuals had only a slightly increased risk 
of psoriasis (15), whereas data from a US cohort of wo-
men demonstrated a stronger association with overweight 
and a close to three-fold increased risk of psoriasis if 
severely obese (16, 17). Also, the cohort displayed in-
creasing risk of psoriasis according to adult weight gain 
(16). To our knowledge, the long-term effect of weight 
gain on psoriasis risk has not been investigated in men. 
There are indications that there could be a difference in 
the aetiology of psoriasis of the late-onset (onset after 
age 40–50 years) vs. early-onset type, and it is hypo-
thesized that late-onset psoriasis may be more related 
to modifiable environmental factors (i.e. overweight); 
however, the results are not conclusive (16, 18–20). 
Smoking is an established risk factor for psoriasis (21). 
A multiplicative effect of obesity and tobacco use was 
suggested in an Italian case-control study (22), but so far 
this possible synergism has not been investigated using 
prospective data. 
Longitudinal investigations that may reveal possible 
relationships between changes in lifestyle factors and 
the observed doubling of psoriasis prevalence are 
needed (6). Thus, the primary aim of this study was to 
investigate the association between overweight, weight 
gain and the risk of psoriasis within a longitudinal 
population-based cohort; also considering variations 
according to sex and age, as well as potential synergism 
between overweight and smoking.
MATERIALS AND METHODS 
Study population 
Data for the present analysis were generated from the multi-
purpose population-based Tromsø Study, which includes 6 
repeated health surveys (T1–T6) in the period 1974 to 2008; 
the design and cohort profile have been described in detail else-
where (23, 24). Whole birth cohorts and random samples of the 
population in the municipality of Tromsø, Norway, 69°N, were 
invited based on the official population registry. 
In the current prospective analysis of overweight and weight 
gain in relation to risk of psoriasis, T4 (1994 to 1995) was 
used as baseline and self-reported psoriasis status in follow-up 
surveys T5 (2001) or T6 (2007 to 2008) was used as outcome 
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variable. In T4, all subjects born earlier than 1970 were invi-
ted, and 77% attended (23). A total of 26,957 participants with 
valid consent were available for the analysis. In this cohort, 
data on psoriasis status in T5 (7-year follow-up) and/or T6 (13-
year follow-up) was available for 11,328 individuals. Further 
exclusion criteria were applied using baseline data in T4: age 
≥ 70 years (n = 547); missing data on self-reported psoriasis 
(n = 1,106); self-reported psoriasis diagnosis (prevalent di-
sease) (n = 739); being pregnant (n = 100); missing measured 
body mass index (BMI) (n = 7); and missing smoking status T4 
(n = 8) or smoking only cigars and pipe (n = 69). A total of 8,752 
individuals aged 25–69 years were included in the analysis, 
with baseline BMI as main predictor. In the analysis of gain 
in BMI and weight from age 25 years, 26 individuals with age 
< 26 years at baseline were excluded to ensure that they did not 
have psoriasis within one year of study enrollment (i.e. reverse 
causation), and a further 384 individuals were excluded due 
to missing report of weight at 25 years, giving a study sample 
of 8,342 individuals. 
Data collection
Clinical measurements. Trained health professionals made all 
clinical measurements according to standardized procedures 
(23, 24). Height (cm) and weight (kg) were measured with par-
ticipants wearing light clothes and no shoes. Body mass index 
(BMI) was calculated as weight divided by height squared (kg/
m2). In T4, blood pressure was recorded 3 times in a sitting 
position after 2 min rest, by an automatic blood pressure mea-
surement device (Dinamap Vital Signs Monitor 1846, Critikon, 
GE Healthcare, Norway), and the mean of the 2 last readings 
was used. Non-fasting blood samples were collected from an 
antecubital vein and analysed at the accredited Department of 
Laboratory Medicine, University Hospital of North Norway, 
Tromsø, Norway (24). Serum total cholesterol and triglyceride 
analyses were performed by enzymatic colorimetric methods 
with commercial kits (CHOD-PAP for cholesterol and GPO-PAP 
for triglycerides; Boehringer–Mannheim, Mannheim, Germany). 
Serum high-density lipoprotein (HDL) cholesterol was measured 
after the precipitation of lower density lipoprotein with heparin 
and manganese chloride. 
In T5 and T6, participants were asked; “Estimate your body 
weight when you were 25 years old? (in kg)”. The first survey 
with available data was chosen. For validation purposes, we 
assessed the correlation between self-reported and measured 
weight among 532 women and 368 men who recalled their 
weight at age 25 years in T5 or T6 and had their actual weight 
at age 24–26 years measured in one of the former surveys, 
T2–T4. Pearson correlation coefficient (R) was 0.89 (women, 
R = 0.80; men, R = 0.79). Self-reported weight at age 25 years 
and measured height in T4 was used to estimate BMI at age 
25 years, and adult change in weight and BMI was estimated 
as the difference from age 25 years until participation in the 
baseline survey, T4.
Questionnaire data – psoriasis and lifestyle variables. In all 
surveys, participants received an invitation letter, and a first 
questionnaire was enclosed with the invitation, while a second 
questionnaire was handed out at the screening centre. The 
second questionnaire was to be returned either at the survey 
site or through the post, and approximately 90–96% of at-
tendees did so (23, 24). The questionnaires are available in 
English and Norwegian at the Tromsø study homepage (www.
tromsostudy.com). 
Life-time self-reported psoriasis was assessed in the second 
questionnaire using the following question; “Do you have or 
have you had psoriasis? (yes/no)” (T4 and T5), and “Do you 
have or have you ever had psoriasis? (yes/no)” (T6). From T6 
the question; “Have you ever been diagnosed with psoriasis by 
a physician?” was added for validation purposes. 
In the baseline survey, T4, participants indicated whether they 
were current daily smokers of cigarettes, cigars or pipe, and 
their smoking history including previous daily smoking, years 
since stopped smoking, total number of smoke-years, and mean 
daily number of cigarettes or weekly number of tobacco packs. 
Information on alcohol intake included number of units of 
wine, beer and spirits consumed within a representative 2-week 
period. Participants indicated their usual level of recreational 
physical activity as the mean weekly number of hours (0, <1, 
1–2, 3+ h) spent doing light activities (not sweating or out of 
breath) and hard activities (sweating/out of breath) separately. 
Statistical analysis
Due to the known differences in body weight distribution 
as well as smoking patterns between men and women, most 
analyses were presented both combined and stratified by sex. 
Descriptive characteristics at baseline (T4) were reported with 
means (standard deviation; SD) for continuous variables and 
numbers (proportions) for categorical variables within 2 BMI 
categories; BMI < 28 and ≥ 28 kg/m2. BMI of 28 kg/m2 has 
been identified as an optimal cut-off value in assessing type 2 
diabetes risk in Caucasians (25). p-values for differences bet-
ween the categories of BMI were assessed using Student’s t-test 
for continuous variables and χ2 tests for categorical variables. 
Smoking status was analysed as a categorical (never, past or 
current smoking) and as a dichotomous variable (never or past 
vs. current smokers), while pack-years smoked was analysed 
as a continuous variable (number of cigarettes per day × num-
ber of years smoked/20) and as a categorical variable (0, 1–9, 
10–19, 20+ pack years). Education was dichotomized into high 
educational level (above high-school/A-level) vs. others. The 
physical activity score was calculated as the sum of hours of light 
and heavy physical activity in spare time per week, with heavy 
physical activity given double weighting (26). Mean daily (g/
day) intake of alcohol was computed from the number of units 
of intake of wine (16.6 g/unit), beer (11.7 g/unit) and spirits (7.4 
g/unit) within a representative 2-week period. 
Incidence proportions of psoriasis were calculated as the 
number of incident cases in T5 and T6 divided by the total 
population without psoriasis at baseline. BMI at baseline was 
assessed both as a continuous, dichotomous, and categorical 
variable (modified according to WHO, where the 2 lowest ca-
tegories < 25 kg/m2 were combined) in both age-adjusted and 
multivariable logistic regression analysis including also sex, 
current smoking (yes/no), mean daily alcohol intake (g/day), 
and the recreational physical activity score. 
For the analysis of adult change in BMI and weight, sex and 
age-specific Z-scores and quartiles were calculated within 5-year 
age groups (age at baseline; 26–< 30, 30–< 35, …65–< 70 years). 
Z-scores for change in BMI and weight were computed by sub-
tracting the sample mean from the individual value and dividing 
the difference by the sample SD. To test whether change in BMI 
from age 25 years to baseline influenced the risk of psoriasis, 
we used multivariable logistic regression models adjusted for 
current smoking (yes/no), mean daily alcohol intake (g/day), 
recreational physical activity score, and mean of BMI at age 25 
years and at baseline. Risk estimates were minimally affected 
after adjustment for other potential confounding lifestyle factors, 
and thus these covariates were omitted from the final models 
(i.e. educational level). 
Potential statistical interactions by sex, age and smoking status 
were explored by testing the significance of multiplicative terms 
added to the multivariable models. We also investigated “biolo-
gical interaction” between overweight and smoking, as defined 
by Rothman (27). Biological interaction between overweight 
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and smoking were analysed using the Synergy index score (27), 
defined as equal to [odds ratio (OR)11–1]/ [(OR01–1) + (OR10–1)], 
where OR11 is the OR for psoriasis associated with the exposures 
combined, whereas OR01 and OR10 are ORs for psoriasis associated 
with the single exposures (in absence of the other exposure). All 
ORs are calculated using those non-exposed to each of the single 
exposures as reference category. Thus, the Synergy index score 
indicates if the risk in double-exposed is higher than expected 
based on the assumption of an additive effect exerted by the single 
exposures. A score exceeding 1.0 indicates interaction and a score 
below 1.0 indicates an antagonistic effect.
All p-values were 2-sided using a 5% significance level. The 
analyses were performed with SAS 9.2 (SAS Institute Inc., 
Cary, NC, USA) and SPSS 21 (SPSS Inc., Chicago, IL, USA).
Ethics
Each participant gave written informed consent prior to the 
examinations. The study was approved by the Norwegian Data 
Protection Authority and the Regional Committee for Medical 
and Health Research Ethics, North Norway. 
RESULTS
The distribution of all baseline characteristics, except al-
cohol intake in men, varied significantly across the BMI 
categories (Table I). Compared with individuals with 
BMI below 28 kg/m2 those with more overweight were 
older, had higher blood pressure, more abnormal lipid 
profiles, lower level of education, smoked less and were 
less physically active. In women, more overweight and 
obesity was associated with lower alcohol consumption. 
The incidence proportion of psoriasis during 7–13 
years of follow-up was 4.7% in both women and men. 
We found a statistically significant relationship be tween 
BMI and risk of psoriasis for both sexes combined. For 
each 2.5 unit increase in BMI the odds for psoriasis in-
creased by 8% (multivariable adjusted model, OR 1.08, 
95% confidence interval (95% CI): 1.01, 1.16) (Table 
II). In multivariable analysis using WHO definitions 
of overweight (25–< 30 kg/m2) and obesity (≥ 30 kg/
m2), obese women tended to have an increased risk of 
psoriasis compared with normal weight (BMI < 25 kg/
m2) women (OR 1.48, 95% CI: 0.94, 2.31), while for 
women and men combined the association was slightly 
attenuated. As there was no increase in risk of psoriasis 
associated with overweight when starting from BMI 25 
kg/m2 in our data, we searched for a possible threshold 
at each higher level of BMI (per kg/m2). There was an 
association from BMI 27 kg/m2 in the total population 
(BMI above vs. below 27 kg/m2; multivariable model, 
OR 1.32, 95% CI: 1.06, 1.64), with a borderline signi-
ficant association in women (OR 1.36, 95% CI: 0.99, 
1.88). For both sexes combined, BMI above vs. below 
28 kg/m2 was associated with a 43% increase in the 
risk of psoriasis (multivariable model, OR 1.43, 95% 
CI: 1.13, 1.81), and a similar association was seen in 
both women and men separately, with no age and sex 
interactions. When stratifying by smoking status to 
separate the effect of BMI and smoke, strengthening 
of the association between overweight and obesity and 
risk of psoriasis was observed in non-smokers; with 
BMI ≥ 30 kg/m2 OR was 1.71 (95% CI: 1.13, 2.56) for 
both sexes combined (P for interaction 0.14; Table SI1). 
A set of sensitivity analysis were performed to eva-
luate the robustness of the results. Effect estimates 
from age-adjusted analysis including only individuals 
who had complete information on all covariates, dif-
Table I. Baseline characteristics according to body mass index (BMI, kg/m2) for women and men in Tromsø 4; n = 8,752a
Women (n = 4,588) Men (n = 4,164)
< 28 kg/m2 ≥ 28 kg/m2 p-value < 28 kg/m2 ≥ 28 kg/m2 p-value
Total, n (%) 3,728 (81.3) 860 (18.7) 3,233 (77.6) 931 (22.4)
Age, years, mean (SD) 46.3 (11.9)   51.9 (11.0) < 0.001 47.4 (11.9) 49.7 (10.6) < 0.001
Higher educationb, n (%) 1,112 (29.9) 150 (17.5) < 0.001 1,077 (33.4) 276 (29.7) 0.036
Height, cm, mean (SD) 164.1 (6.1) 162.6 (6.1) < 0.001 177.5 (6.7) 176.6 (6.8) < 0.001
Weight, kg, mean (SD) 62.9 (7.5) 82.5 (9.7) < 0.001 77.4  (8.4) 94.3 (9.8) < 0.001
BMI, kg/m2, mean (SD) 23.3 (2.4) 31.2 (3.0) < 0.001 24.5 (2.0) 30.2 (2.2) < 0.001
Systolic blood pressure, mmHg, mean (SD) 125.6 (18.3) 140.4 (22.1) < 0.001 132.9 (16.0) 140.0 (17.4) < 0.001
Diastolic blood pressure, mmHg, mean (SD) 73.0 (11.1) 80.6 (12.2) < 0.001 77.6 (11.0) 83.1 (11.7) < 0.001
Total cholesterol, mmol/l, mean (SD) 5.98 (1.32) 6.69 (1.27) < 0.001 6.08 (1.21) 6.46 (1.14) < 0.001
High-density lipoprotein cholesterol, mmol/l, mean (SD) 1.70 (0.40) 1.53 (0.37) < 0.001 1.40 (0.36) 1.24 (0.30) < 0.001
Triglycerides, mmol/l, mean (SD) 1.18 (0.70) 1.77 (0.95) < 0.001 1.59 (0.98) 2.33 (1.44) < 0.001
Alcohol, g/day, mean (SD) 2.88 (4.02) 1.91 (3.04) < 0.001 4.85 (5.82) 4.52 (5.99) 0.14
Physical activity score, mean (SD) 3.13 (2.19) 2.50 (1.94) < 0.001 3.68 (2.57) 3.15 (2.46) < 0.001
Smoking status, n (%)
  Never smoker 1,458 (39.1) 404 (47.0) < 0.001 1,041 (32.2) 259 (27.8) < 0.001
  Prior smokerc 962 (25.8) 236 (27.4) 1,121 (34.7) 400 (43.0)
  Present smoker 1,308 (35.1) 220 (25.6) 1,071 (33.1) 272 (29.2)
aNumbers may vary due to missing data. bAbove high school/A-level. cYear since smoke cessation; Women: range 0–45 years, median 10 years; Men: range 
0–46 years; median 14 years.
Values are given as mean (standard deviation; SD) and number (%). 
p-value; Student’s t-test for continuous variables or χ2 test for categorical variables.
1http://www.medicaljournals.se/acta/content/?doi=10.2340/00015555-2530
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fered only slightly from the presented estimates. Also, 
estimates did not change in analysis with uniform 
follow-up time, using only outcome data from T6 (2007 
to 2008). When including those with missing psoriasis 
data at baseline in the analysis, the association between 
overweight, obesity and risk of psoriasis was slightly 
strengthened; for both sexes combined, BMI ≥ 28 kg/
m2; OR 1.46 (95% CI: 1.18, 1.79), and BMI ≥ 30 kg/m2; 
OR 1.78 (95% CI: 1.25, 2.54) in non-smokers.
There was a dose-response relationship between BMI 
gain from age 25 years to baseline (T4) and psoriasis 
incidence in the age group 45 years and older at baseline 
(p for linear trend over quartiles=0.009), with an up to 
70% increased odds in the top quartile compared with 
the bottom quartile (multivariable model, OR 1.70, 95% 
CI: 1.13, 2.55), while in the younger age group there 
was no association (p for interaction=0.03) (Table III). 
For both sexes and age groups bottom quartile equalled 
a less than 2 unit increase in BMI from age 25 years 
up to the baseline survey. Cut-offs for quartiles of BMI 
change within 5-years age groups are shown in Fig. S11. 
When using adult weight gain (weight change from 
age 25 years to baseline) as main predictor in the mo-
dels, the association with risk of psoriasis was further 
strengthened from age 45 years, OR 1.90 (top vs. bot-
tom quartile 95% CI 1.28, 2.82), p-trend = 0.002, p for 
interaction=0.02. There were no statistically significant 
interactions with sex or smoking status. Sensitivity 
analysis limited to those with 13 years’ follow-up (T6) 
gave almost the same risk estimates, as did the inclu-
sion of observations with missing psoriasis data in the 
baseline population. 
Smokers presented with almost doubled incidence 
proportions of psoriasis compared with non-smokers; 
6.7% vs. 3.7%, as also reflected in the 1.70–2.16-times 
increased odds for psoriasis in smokers estimated from 
the multivariable analysis (Table SII1). There was a sig-
nificant dose-response relationship between pack-years 
smoked and risk of psoriasis in women (p <0.003) and 
for both sexes combined (p < 0.001). In multivariable 
analysis of combined exposure to overweight/obesity 
and smoking, there was no indication of a multiplicative 
association and biological interaction using SI-scores 
(Table II). The simultaneous exposure to smoking and 
overweight ≥ BMI 28 kg/m2 gave the highest incidence 
proportions of psoriasis, with 7.7 and 7.4% in women 
and men, respectively, vs. 3.1% and 3.5% in those not 
exposed to either, multivariable adjusted OR 2.48 (95% 
CI: 1.70, 3.63). Redefining those stopping smoking 
within the last 12 months before baseline as current 
smokers, did not influence the results. 
DISCUSSION
The results of this large prospective study indicate that 
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men display more than 40% increased risk of psoriasis, 
which was further increased in obese non-smokers reach-
ing 70%. Adult gain in BMI or weight was associated 
with a 70–90% increased risk of late-onset psoriasis for 
both sexes, independent of BMI or weight category. Smo-
king almost doubled the risk of psoriasis; however, there 
was no indication of a synergism between overweight 
and smoking on the risk of psoriasis.
There are both strengths and limitations to this 
study. Firstly, the selection of participants from a large 
population-based cohort with high attendance rates in 
repeated health surveys generally allows for a more 
truthful evaluation of the relationship between over-
weight, weight gain, smoking and risk of psoriasis. 
Also, the data include comprehensive assessment of 
lifestyle factors and clinical examinations using stan-
dardized and validated methods (24). Selection bias is 
usually more limited in general health surveys. Studies 
within the Tromsø study cohort indicate that there is 
a chance that obese individuals and smokers may be 
slightly under-represented in the cohort (6, 23, 24). 
The subjects who have declined participation tend to 
be younger or very old, male and single (23, 24).
Self-report of psoriasis is a widely used method in 
epidemiological studies (2, 6, 10, 28, 29). Approximately 
90% of psoriasis cases are classical plaque phenotypes 
(30), which according to validation studies from compa-
rable populations, are adequately diagnosed by trained 
general practitioners (31–33), who attend to the majority 
of patients with psoriasis in Norway. Among those with 
self-reported psoriasis in T6, approximately 90% of 
women and 84% of men confirmed a doctor’s diagnosis 
(6), and the reproducibility of self-reported psoriasis 
between the first 4 surveys and T6 was high (6). A recent 
Norwegian study from a similar cohort showed that self-
report of psoriasis was a valid method with a positive 
predictive value (PPV) of 78% (10). Due to the relatively 
low sensitivity (i.e. high number of false negatives) the 
estimated true prevalence of psoriasis was 8% vs. 5.8% 
as reported in the cohort (10, 34). Data from the US Nur-
ses’ Health Study showed that 92% of reported psoriasis 
cases were definite cases of psoriasis (17). Also, prior 
studies suggest that up to half of mild psoriasis cases may 
go undiagnosed by a doctor (28, 35, 36), which could 
potentially attenuate the effect estimates. 
In line with others, we also found that persons with 
skin disease tend to not seek medical attention (28, 
37–39), and that there may be a sex difference in the 
degree that they seek medical consultation (6, 37). The 
validity of self-reported prior weight was acceptable 
in a former US study (40). This is in line with data in 
the Tromsø study. Prior studies from the Norwegian 
population have also shown acceptable validity of self-
reported smoking (41–43). 
The approximate 6-year time laps between the sur-
veys gives some uncertainty as to when in the time 
period their psoriasis, BMI or smoking status may have 
changed. However, the degree of tracking in weight is 
high in the Tromsø cohort (44). In general, women have 
become overweight in the time period after the baseline 
survey in 1994 to 1995 (6). Thus, the association bet-
ween change in BMI and incident psoriasis in women 
might be more difficult to disentangle in our data. An 
earlier study supported that short-term weight gain does 
not seem to be an important risk factor for incident pso-
riasis (45). Ideally, we would have had more detailed 
information on body composition, including abdominal 
adiposity (e.g. waist circumference), at baseline.
It is possible that the association of BMI with in-
cident psoriasis could be confounded or modified by 
other factors. There may be residual confounding from 
factors either unknown or not included in our analysis, 
for example genetic susceptibility. A possible confoun-
der is dietary composition, including high salt intake, 
which has been associated both with diets composed of 
highly processed foods and with autoimmune disease 
(46, 47). Tromsø has subarctic climate conditions with 
more than 5 months of negligible ultraviolet radiation 
Table III. Incidence proportion (IP) and odds ratio (OR) for psoriasis in Tromsø 5 (2001) or Tromsø 6 (2007 to 2008) by change in 
















% < 45 years ≥ 45 years Pinteraction < 45 years ≥ 45 years Pinteraction
Z-score 3,138 126 4.0 5,204 260 5.0 1.02 (0.86, 1.22) 1.11 (0.98, 1.25) 0.46 1.03 (0.85, 1.25) 1.15 (0.99, 1.32) 0.51
Q1 780 35 4.5 1,300 52 4.1 1.0 (Ref.) 1.0 (Ref.) 0.03 1.0 (Ref.) 1.0 (Ref.) 0.03
Q2 789 33 4.2 1,303 58 4.6 0.93 (0.57, 1.51) 1.05 (0.72, 1.54) 0.96 (0.59, 1.57) 1.25 (0.85, 1.84)
Q3 787 30 3.8 1,301 69 5.3 0.84 (0.51, 1.39) 1.27 (0.88, 1.82) 0.89 (0.54, 1.48) 1.44 (0.97, 2.12)
Q4 782 28 3.6 1,300 81 6.0 0.79 (0.48, 1.31) 1.45 (1.01, 2.06) 0.79 (0.46, 1.35) 1.70 (1.13, 2.55)
Ptrend 0.33 0.02 0.37 0.009
aCrude logistic regression model. bMultivariable logistic regression model including current smoking, daily alcohol intake, recreational physical activity 
score, and mean of BMI at age 25 years and at baseline.
Z-score: age-specific (approximately 5-year intervals; 26–< 30, 30–< 35, … ,, 60–< 65, 65–< 70) and sex-specific z-score of change in BMI from age 25 
years to baseline. Q1–4: age-specific (approximately 5-year intervals; 26–<30, 30–<35,…,, 60–<65, 65–<70) and sex-specific quartiles of change in BMI 
from age 25 to baseline.
95% CI: 95% confidence interval.
Acta Derm Venereol 97
6 K. Danielsen et al.
exposure, making inhabitants vulnerable to vitamin 
D deficiency. Vitamin D has been inversely linked to 
severity of psoriasis (48). As increasing BMI leads to 
decreased levels of circulating vitamin D, it is possible 
that the obesity epidemic may be especially important 
to health in the Tromsø cohort (48). 
Our results are in line with findings from comparable 
studies showing a relationship between overweight, 
obesity and incident psoriasis (15–17). In the women 
in the US Nurses’ Health Study, increasing risk of pso-
riasis within increasing BMI categories was reported, 
with relative risk (RR) 1.40 in the overweight, 1.48 
in the obese, and 2.69 in the severely obese category 
(16), as further supported by a later study (17). A study 
including both sexes from the UK General Practice 
Research Database also found that overweight and 
obesity represent risk factors for psoriasis, with an 
11% and 33% increase in odds, respectively (15). Our 
analysis also supports that overweight and obesity are 
risk factors for psoriasis in both men and women. Our 
stratified analysis of smoking status, performed in order 
to further adjust for tobacco as a confounder, allowed us 
to demonstrate a 70% increased odds of psoriasis among 
obese individuals. Even though a linear association was 
observed between BMI and odds of psoriasis, data show 
that this was explained merely by the increased risk 
above the found threshold. We did not have a sufficient 
number of severely obese cases to further investigate 
this association. 
To our knowledge this is the first prospective study 
investigating weight gain as a risk factor for psoriasis 
onset in men; belonging to the upper quartile of BMI or 
weight gain led to a 70–90% increased odds of psoriasis 
among persons from middle-age, with a dose-response 
relationship for both BMI and weight gain. In the US 
Nurses’ Health Study cohort, the RR of psoriasis in 
women in the highest weight gain category was up to 
1.88, and a positive trend was also observed here (16). 
Our results suggest that adult weight gain may be a 
more important risk factor for psoriasis among late-
onset cases, as supported by a recent study in which 
patients with late-onset psoriasis had a higher propor-
tion of obesity and elevated waist circumference than 
the early-onset group (18). Setty et al. did not report 
any interaction between age and overweight as a risk 
factor for psoriasis (16). However, the investigated wo-
men were mainly more representative of the late-onset 
psoriasis group. Furthermore, as the obesity epidemic in 
the US is more established, their mean BMI may have 
already been increased at a younger age. The associa-
tion between BMI and late-onset cases could be due to 
the prolonged and cumulative negatively influencing 
inflammation due to overweight/obesity, which can no 
longer be compensated for by the individual. Moreover, 
it can be related to interactions with weakly predispo-
sing genetic or epigenetic factors. 
Smoking was a strong risk factor for psoriasis in 
our data, as also indicated by others (22, 49, 50). A US 
cohort study found current smoking to be a strong pre-
dictor of psoriasis development, with a dose-dependent 
increasing risk between 1.8 and 2.7 (51). Although 
there was no statistically significant sex interaction in 
our data, smoking seemed to be a stronger risk factor 
for psoriasis among women, demonstrating dose-
dependency between pack-years smoked and odds of 
psoriasis, as also indicated by others (22, 49). While a 
multiplicative effect of overweight and smoking was 
suggested in an Italian case-control study (22), this 
synergism could not be confirmed by our data. Howe-
ver, in our cohort, overweight smokers had the highest 
incidence of psoriasis, suggesting an additive effect. 
Our findings are supported by known biological me-
chanisms. Obesity is in itself characterized by low-level 
inflammation (52), and basic research indicates that 
adipocytes and activated inflammatory macrophages 
can play a role in both psoriasis and overweight/obe-
sity (13). Adipose tissue produces several hormones, 
adipokines, and pro-inflammatory cytokines important 
in psoriasis, among these interleukin (IL)-1, IL-6 and 
tumour necrosis factor alpha (TNF-α) (13, 53–56). 
Increased production of pro-inflammatory cytokines 
is also seen in chronic smoking due to oxidative stress 
and effects on both the innate and adaptive immune 
system (51, 57–59). Thus, it is biologically plausible 
that overweight and smoking may fuel the development 
of psoriasis in genetically predisposed individuals (53). 
There may be shared genetic variants that increase 
susceptibility to both obesity and psoriasis (60). Ho-
wever, in a meta-analysis of 4 psoriasis genome wide 
association study cohorts there was no differences bet-
ween psoriasis cases and controls in a weighted gene 
risk score investigating single nucleotide polymorp-
hisms associated with increased BMI (61). Epigenetic 
mechanisms have recently emerged as a putative link 
between genetic and environmental factors in psoriasis, 
meaning that environmental factors can lead to activa-
tion or deactivation of specific genes of importance for 
disease development (62–64).
The longitudinal study design allows us to determine 
that obesity precedes psoriasis and is a risk factor for 
psoriasis development. The relatively strong effect 
estimates, dose-response relationship, biological plau-
sibility, as well as consistency with other studies sup-
port that this may be a causal relationship. Overweight 
and smoking represent modifiable risk factors that may 
be targets for both primary prevention as well as sup-
portive treatment of psoriasis. Interestingly, 2 recent 
randomized controlled trials showed clinical improve-
ment of psoriasis through a low-energy diet (65, 66). 
Furthermore, the association between overweight and 
psoriasis is of great importance in relation to potential 
comorbid conditions, as abdominal adiposity is the 
Acta Derm Venereol 97
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hallmark component of the metabolic syndrome, a ma-
jor risk factor for cardiovascular disease and diabetes. 
More studies investigating the effect of weight loss and 
smoking cessation on psoriasis severity and treatment 
response are warranted.
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Supplementary material to article by K. Danielsen et al. ”Overweight and Weight Gain Predict Psoriasis Development in a Population-
based Cohort”
Table SII. Incidence proportion (IP) and odds ratio (OR) for psoriasis in Tromsø 5 (2001) or Tromsø 6 (2007 to 2008) by smoking status 
at baseline Tromsø 4 (1994 to 1995); n = ,387 in multivariable  logistic regression model












 % Women Men Total population
Present smoking
  Non-smoker 3,060 105 3.4 2,821 111 3.9 1.0 (Ref.) 1.0 (Ref.) 1.0 (Ref.)
  Smoker 1,528 109 7.1 1,343 84 6.3 2.16 (1.62, 2.88) 1.70 (1.26, 2.29) 1.92 (1.56, 2.37)
Smoking history
  Never 1,862 60 3.2 1,300 59 4.5 1.0 (Ref.) 1.0 (Ref.) 1.0 (Ref.)
  Pastb 1,198 45 3.8 1,521 52 3.4 1.10 (0.74, 1.65) 0.70 (0.47, 1.04) 0.91 (0.69, 1.20)
  Present 1,528 109 7.1 1,343 84 6.3 2.24 (1.61, 3.14) 1.41 (0.99, 2.01) 1.84 (1.44, 2.35)
  Ptrend < 0.001 0.029 < 0.001
Pack-years
  0 1,931 64 3.3 1,355 60 4.4 1.0 (Ref.) 1.0 (Ref.) 1.0 (Ref.)
  1–9 1,475 76 5.2 1,029 40 3.9 1.54 (1.09, 2.19) 0.91 (0.60, 1.38) 1.24 (0.95, 1.62)
  10–19 808 49 6.1 890 38 4.3 1.82 (1.23, 2.68) 0.95 (0.61, 1.46) 1.36 (1.02, 1.82)
  20 + 374 25 6.7 890 57 6.4 1.69 (1.01, 2.84) 1.50 (1.00, 2.26) 1.71 (1.25, 2.33)
  Ptrend 0.003 0.078 0.001
aWomen and men: multivariable model including age, daily alcohol intake, body mass index, and recreational physical activity score; Total population: 
additionally adjusted for sex.
Fig. S1. Quartiles (Q1–4) and means of change in body mass index (BMI) from age 25 years to 
baseline in Tromsø 4 (1994 to 1995) according to age-group in women (n = 4,368) and men (n = 3,974). 
The Tromsø Study.
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